Skip to main navigation Skip to search Skip to main content

Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability

  • Meera Mohan
  • , Natalie Danziger
  • , Othman Salim Akhtar
  • , Ravi Narra
  • , Marcello C. Pasquini
  • , Sabarinath Radhakrishnan
  • , Binod Dhakal
  • , Anita D'Souza
  • , Douglas Lin
  • , Caleb Ho
  • , Razelle Kurzrock

Research output: Contribution to journal › Article › peer-review

Abstract

Plasma cell leukemia (PCL) is rare and aggressive. Plasma cells from patients with PCL were examined using next-generation sequencing (NGS). We compared NGS data from 18 patients with PCL (peripheral blood, n = 10; bone marrow, n = 8) and 1742 multiple myeloma (MM) samples. Mutations of TP53, CCND1, and KRAS were commonly observed in both diseases. Alterations in DIS3 (17% vs 1%), CCND2 (22% vs 15%), PIK3R1 (6% vs 0%), and MAP3K1 (6% vs 2%) were more common in PCL than in MM (P < .05). Translocations occurred in 11 (61.1%) patients with PCL; IGH::CCND1 and IGH::MYC were more frequent in PCL than in MM (22% vs 14%, P = not significant and 11% vs 1%, P < .05, respectively). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.

Original languageEnglish (US)
Pages (from-to)1400-1404
Number of pages5
JournalBlood Advances
Volume10
Issue number4
DOIs
StatePublished - Feb 24 2026
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability'. Together they form a unique fingerprint.

Cite this